Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies
about
Fish oil supplements for rheumatoid arthritisEthnopharmacological in vitro studies on Austria's folk medicine--an unexplored lore in vitro anti-inflammatory activities of 71 Austrian traditional herbal drugsVascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsInitial treatment of complete rotator cuff tear and transition to surgical treatment: systematic review of the evidenceNSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen SpeciesImpairment of aspirin antiplatelet effects by non-opioid analgesic medicationNew insights into the use of currently available non-steroidal anti-inflammatory drugsIncreased cardiovascular mortality associated with gout: a systematic review and meta-analysisPiroxicam-β-cyclodextrin: a GI safer piroxicamGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEOWhy drug safety should not take a back seat to efficacyLaboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort studyRisk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias ToolClinical Pharmacology and Cardiovascular Safety of NaproxenCyclooxygenase-2 and the inflammogenesis of breast cancer.The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.Vascular COX-2 modulates blood pressure and thrombosis in mice.Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksThe impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.Data Resource Profile: Danish online drug use statistics (MEDSTAT).Practice guidelines for pharmacists: The management of osteoarthritis.COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks.Anti‑inflammatory effects of oxymatrine on rheumatoid arthritis in rats via regulating the imbalance between Treg and Th17 cellsRisk of stroke in patients with rheumatism: a nationwide longitudinal population-based study.Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications.Knee Symptomatic Osteoarthritis, Walking Disability, NSAIDs Use and All-cause Mortality: Population-based Wuchuan Osteoarthritis StudyIschaemic cardiovascular risk and prescription of non-steroidal anti-inflammatory drugs for musculoskeletal complaints.Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)Etoricoxib and the treatment of ankylosing spondylitis.Advances in NSAID development: evolution of diclofenac products using pharmaceutical technologyCyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice.Celecoxib for osteoarthritis.The effect on knee-joint load of instruction in analgesic use compared with neuromuscular exercise in patients with knee osteoarthritis: study protocol for a randomized, single-blind, controlled trial (the EXERPHARMA trial).Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries.Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidanceLow-dose SoluMatrix diclofenac : a review of safety across two Phase III studies in patients with acute and osteoarthritis pain.Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatmentLC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression
P2860
Q24197686-AAF17414-FBD6-4DCB-884D-06389A02F038Q24613065-6B1360B9-28DD-4910-A901-69F2E3BDBDE0Q24619410-77CE85EA-5F4E-4915-AA3C-D607D17F9D42Q26743447-3CAE3AB2-C880-43B9-910B-776007B8A17BQ26784322-3358B872-A3A4-42A8-A0EE-11AEAFE78C02Q26801633-AD4A78D6-8E06-4F9B-8645-56FE017DCF77Q26852330-2CE9D01D-7F10-497A-8F25-EDEA233A0EE7Q27000643-7A69F824-0836-4DED-881F-0BF50FB9AC35Q27023475-D6EE009C-0176-499D-82CC-3E92C6C0F0BBQ27026351-02802D65-DCF9-4856-BFD0-A28253E45B06Q28079515-9FFB92F6-7542-46F1-A635-F6A5035FEFB3Q28477237-FA604CE2-8BB4-43AB-A362-84C2542EECC2Q28481677-4FE26B5C-D093-4250-8D1F-E2EA137F8475Q28551188-632C8C05-9BC3-411B-8670-231598058C8EQ30360728-691BC48B-6AEC-4D3C-B584-150054F9C2DCQ30367680-0FC17522-B256-4C50-ACB5-7BB111DDE8EAQ30415171-CB2DC03F-ABA1-429D-A5A2-2B609CE785BEQ30540294-6DA159AE-F5D3-4C35-9E86-469BF7C5928DQ30562262-307C243C-4543-4AFC-B21C-62D8FB7A5704Q30629677-E255EFCC-B5D8-4DCF-BF98-49DC473733DEQ30791071-810DF45D-80BC-4335-B4EC-1D5FB4A45159Q31145026-DA10907F-B6E0-495E-B8E3-BCDEC7404B83Q33632527-0A6FAF54-F753-4234-BB5E-4B989DD3A1B0Q33699097-8C724A2C-DCFF-4B24-A0F3-BCDD30C0E493Q33702253-4D2FA07F-CAB9-4777-9D03-D396D55C662DQ33714074-CA9926CB-0A13-473D-AB29-333D248FD834Q33757082-F4F51259-56D5-4C44-8EB6-D346B13DAA74Q33789803-C9D36B62-C18F-4449-A4D5-D19499C6BE83Q33821026-8C05755C-2B72-4059-B69E-9F621132615CQ34310573-63DD4F93-2DFD-4554-ADDF-E791B849D0ABQ34466689-7797F049-A0CC-424B-88FC-73E238C7E96FQ34475981-49C7F114-E2EF-4EF1-B3B3-03DCB8052C90Q34499514-5D519EF7-7028-461E-9C96-C08A0F64B121Q34557021-78A85447-6576-4380-BB4D-934312886ED4Q34558495-4EE264E0-FFE6-4776-9ADF-EC2A04F7166EQ34592490-78300324-F0DE-48C8-B53F-976B210FC566Q34655792-5F0F2F75-ECB1-4DAF-8278-1E2BBD5932BBQ34669949-25230EB5-743B-4332-97CD-23D62A6ED9B2Q34705364-47E48902-F0A1-436F-A838-3CC5BCDEAD4CQ34854231-FC60177D-DB3B-47C5-8873-96FE963D5E88
P2860
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cardiovascular risk with non-s ...... ntrolled observational studies
@ast
Cardiovascular risk with non-s ...... ntrolled observational studies
@en
Cardiovascular risk with non-s ...... ntrolled observational studies
@en-gb
Cardiovascular risk with non-s ...... ntrolled observational studies
@nl
type
label
Cardiovascular risk with non-s ...... ntrolled observational studies
@ast
Cardiovascular risk with non-s ...... ntrolled observational studies
@en
Cardiovascular risk with non-s ...... ntrolled observational studies
@en-gb
Cardiovascular risk with non-s ...... ntrolled observational studies
@nl
prefLabel
Cardiovascular risk with non-s ...... ntrolled observational studies
@ast
Cardiovascular risk with non-s ...... ntrolled observational studies
@en
Cardiovascular risk with non-s ...... ntrolled observational studies
@en-gb
Cardiovascular risk with non-s ...... ntrolled observational studies
@nl
P2860
P31
P921
P3181
P1433
P1476
Cardiovascular risk with non-s ...... ntrolled observational studies
@en
P2093
Patricia McGettigan
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001098
P407
P50
P577
2011-09-01T00:00:00Z